

In the Claims:

2 Please amend claims 57, 62, 63, and 65 as follows: 2

57. (Amended) The method according to claim 56, wherein the LPA obtained provides a C-terminal presentation of the C-terminal sequence Pro-Lys-Lys-Pro (Seq. ID 7) of OspC.

62. (Amended) The method according to claim 60, wherein at least one of the peptide sequences comprises the ESAT-6, 51-70 sequence or the ESAT-6, 1-17 sequence protein HO-GlnLeuAlaAsnAsnLeu-GluThrAlaThrAlaAspTrpLysGlnGlnValGlyGlnTyr-H (HO-Seq. ID 2-H) of *Mycobacterium tuberculosis* HO-AlaSerAlaAlaAlaGluIleGlyAlaPheAsn-TrpGlnGlnGluThrMet-H (HO-Seq. ID 3-H).

63. (Amended) The method according to claim 46, wherein the LPA obtained is selected from the group consisting of

[LPA-I]: FmocN(CH₂CO-ProValValAlaGluSerProLysLysPro-OH)₂
(FmocN(CH₂CO-Seq. ID 1-OH)₂),

[LPA-II]: biotin-NH(CH₂)₅CON(CH₂CO-ProValValAlaGluSerProLysLysPro-OH)₂ (biotin-NH(CH₂)₅CON(CH₂CO-Seq. ID 1-OH)₂),

[LPA-III] : $\text{NH}_2\text{CH}(\text{CH}_2\text{CO-ProValValAlaGluSerProLysLysPro-OH})_2$

$(\text{NH}_2\text{CH}(\text{CH}_2\text{CO-Seq. ID 1-OH})_2),$

[LPA-IV] : $\text{H-Lys-NHCH}(\text{CH}_2\text{CO-ProValValAlaGluSerProLysLysPro-OH})_2$

$(\text{H-Lys-NHCH}(\text{CH}_2\text{CO-Seq. ID 1-OH})_2),$

[LPA-VII] : $\text{CH}_2(\text{CH}_2\text{CO-}\beta\text{-Ala-}\beta\text{-AlaLysGluProAsnLysGlyValAsnPro-}$

$\text{AspGluVal}\beta\text{Ala-OH})_2 (\text{CH}_2(\text{CH}_2\text{CO-}\beta\text{-Ala-}\beta\text{-Ala-Seq. ID 4-}\beta\text{Ala-OH})_2),$

[LPA-VIII] : $\text{HC}(\text{CH}_2\text{CO-LysGluProAsnLysGlyValAsnProAspGluVal-}$

$\beta\text{Ala})_2\text{COOH} (\text{HC}(\text{CH}_2\text{CO-Seq. ID 4-}\beta\text{Ala})_2\text{COOH}),$

[LPA-IX] : $\text{Fmoc-NHCH}(\text{CH}_2\text{CO-AspArgValTyrIleHisProPheHisLeu-NH}_2)_2$

$(\text{Fmoc-NHCH}(\text{CH}_2\text{CO-Seq. ID 5-NH}_2)_2),$

[LPA-X] : $\text{Aloc-NHCH}(\text{CH}_2\text{CO-AspArgValTyrIleHisProPheHisLeu-NH}_2)_2$

$(\text{Aloc-NHCH}(\text{CH}_2\text{CO-Seq. ID 5-NH}_2)_2) \text{ and}$

[LPA-XI] : $\text{Fmoc-AspProThrGlnAsnIleProProGly-NHCH}(\text{CH}_2\text{CO-AspArg-}$

$\text{ValTyrIleHisProPheHisLeu-NH}_2)_2 (\text{Fmoc-Seq. ID 6-NHCH}(\text{CH}_2\text{CO-Seq. ID}$

$5\text{-NH}_2)_2).$

65. (Amended) The method according to claim 60, wherein the LPA obtained is selected from the group consisting of

E10
[LPA-V]: (HO-ProLysLysProSerGluAlaValValPro-COCH₂)₂CH-NH-Lys-(GlnLeuAlaAsnAsnLeuGluThrAlaThrAlaAspTrpLysGlnGlnValGlyGlnTyr-H)₂
((HO-Seq. ID 12-COCH₂)₂CH-NH-Lys-(Seq. ID 2-H)₂), and

[LPA-VI]: (HO-ProLysLysProSerGluAlaValValPro-COCH₂)₂N-Lys(AlaSer-AlaAlaAlaGluIleGlyAlaPheAsnTrpGlnGlnGluThrMet-H)₂ ((HO-Seq. ID 12-COCH₂)₂N-Lys(Seq. ID 3-H)₂).